文献速递心脑血管急症重症综合管理与镇静镇痛

神经元特异性烯醇化酶预测心脏骤停及目标温度管理后的不良结局:一项1053例患者的多中心研究

Neuron-Specific Enolase Predicts Poor Outcome After Cardiac Arrest and Targeted Temperature Management: A Multicenter Study on 1,053 Patients.
PubMed 文献 · Crit Care Med · 2017-01-01
一句话结论心脏骤停后目标温度管理患者第3天血清NSE>90 μg/L预测不良结局(CPC 4-5)阳性预测值99%,假阳性率0.5%,敏感度48%;NSE≤17 μg/L排除CPC 4-5的阴性预测值92%。

该多中心研究分析了德国、奥地利和意大利5家医院非创伤性院内心脏骤停和院外心脏骤停患者第3天血清神经元特异性烯醇化酶(NSE)浓度与ICU出院时脑功能分类(CPC)的关系,患者均在33°C下治疗24小时。NSE>90 μg/L预测CPC 4-5的阳性预测值99%、假阳性率0.5%、敏感度48%;3例NSE>90 μg/L但CPC 1-2的患者均有NSE升高的混杂因素。NSE≤17 μg/L排除CPC 4-5的阴性预测值92%,14例NSE≤17 μg/L死亡患者多数死因非缺氧缺血性脑病。作者强烈推荐常规量化溶血,并指出NSE升高的混杂因素包括产NSE肿瘤、急性脑疾病和溶血。

要点

  • 心脏骤停后33°C治疗24小时的患者,第3天血清NSE>90 μg/L预测ICU出院时CPC 4-5的阳性预测值99%、假阳性率0.5%、敏感度48%。
  • NSE>90 μg/L但CPC 1-2的3例患者均有NSE升高的混杂因素,作者强烈推荐常规量化溶血。
  • NSE≤17 μg/L排除CPC 4-5的阴性预测值92%;14例NSE≤17 μg/L死亡患者多数死因非缺氧缺血性脑病。
  • NSE对不良结局的预测特异度和敏感度与年龄、性别、初始心律无关,但院外心脏骤停高于院内心脏骤停。
  • NSE升高的混杂因素包括产NSE肿瘤、急性脑疾病和溶血,判读时应主动考虑。

适用人群与场景

  • 德国、奥地利和意大利5家医院的非创伤性院内心脏骤停和院外心脏骤停患者,均在33°C下治疗24小时。
  • 评估时间为心脏骤停后第3天血清NSE浓度,结局为ICU出院时CPC。

诊断标准与关键阈值

  • 血清NSE>90 μg/L预测CPC 4-5,阳性预测值99%,假阳性率0.5%,敏感度48%。
  • 血清NSE≤17 μg/L(正常上限)排除CPC 4-5,阴性预测值92%。

红旗征与不能漏的情况

  • NSE升高的混杂因素包括产NSE肿瘤、急性脑疾病和溶血,作者强烈推荐常规量化溶血。
  • NSE≤17 μg/L且死亡的患者多数死因非缺氧缺血性脑病,判读时需考虑其他死因。

研究设计与关键结果

  • 多中心研究,纳入1053例非创伤性院内心脏骤停和院外心脏骤停患者,来自德国、奥地利和意大利5家医院,均在33°C下治疗24小时。
  • NSE>90 μg/L预测CPC 4-5的阳性预测值99%、假阳性率0.5%、敏感度48%。
  • NSE>90 μg/L且CPC 1-2的3例患者均有NSE升高的混杂因素。
  • NSE≤17 μg/L排除CPC 4-5的阴性预测值92%;14例NSE≤17 μg/L死亡患者多数死因非缺氧缺血性脑病。
  • NSE预测不良结局的特异度和敏感度与年龄、性别、初始心律无关,但院外心脏骤停高于院内心脏骤停。

证据类型、等级与局限

  • 研究类型:多中心研究,样本量1053例,5家医院,人群为非创伤性院内心脏骤停和院外心脏骤停患者。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为90 μg/L是与几乎无假阳性且敏感度可接受的阈值相关的NSE截断值。
  • 作者强烈推荐常规量化溶血。
  • 作者指出NSE升高的混杂因素应主动考虑:产NSE肿瘤、急性脑疾病和溶血。
  • 作者指出NSE≤17 μg/L不支持与苏醒不相容的缺氧缺血性脑病。
  • NSE预测不良结局的准确度不同,院外心脏骤停优于院内心脏骤停。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Outcome prediction after cardiac arrest is important to decide on continuation or withdrawal of intensive care. Neuron-specific enolase is an easily available, observer-independent prognostic biomarker. Recent studies have yielded conflicting results on its prognostic value after targeted temperature management.

DESIGN, SETTING, AND PATIENTS: We analyzed neuron-specific enolase serum concentrations 3 days after nontraumatic in-hospital cardiac arrest and out-of-hospital cardiac arrest and outcome of patients from five hospitals in Germany, Austria, and Italy. Patients were treated at 33°C for 24 hours. Cerebral Performance Category was evaluated upon ICU discharge. We performed case reviews of good outcome patients with neuron-specific enolase greater than 90 μg/L and poor outcome patients with neuron-specific enolase less than or equal to 17 μg/L (upper limit of normal).

MEASUREMENTS AND MAIN RESULTS: A neuron-specific enolase serum concentration greater than 90 μg/L predicted Cerebral Performance Category 4-5 with a positive predictive value of 99%, false positive rate of 0.5%, and a sensitivity of 48%. All three patients with neuron-specific enolase greater than 90 μg/L and Cerebral Performance Category 1-2 had confounders for neuron-specific enolase elevation. An neuron-specific enolase serum concentration less than or equal to 17 μg/L excluded Cerebral Performance Category 4-5 with a negative predictive value of 92%. The majority of 14 patients with neuron-specific enolase less than or equal to 17 μg/L who died had a cause of death other than hypoxic-ischemic encephalopathy. Specificity and sensitivity for prediction of poor outcome were independent of age, sex, and initial rhythm but higher for out-of-hospital cardiac arrest than for in-hospital cardiac arrest patients.

CONCLUSION: High neuron-specific enolase serum concentrations reliably predicted poor outcome at ICU discharge. Prediction accuracy differed and was better for out-of-hospital cardiac arrest than for in-hospital cardiac arrest patients. Our "in-the-field" data indicate 90 μg/L as a threshold associated with almost no false positives at acceptable sensitivity. Confounders of neuron-specific enolase elevation should be actively considered: neuron-specific enolase-producing tumors, acute brain diseases, and hemolysis. We strongly recommend routine hemolysis quantification. Neuron-specific enolase serum concentrations less than or equal to 17 μg/L argue against hypoxic-ischemic encephalopathy incompatible with reawakening.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Streitberger KJ, Leithner C, Wattenberg M, et al. Neuron-Specific Enolase Predicts Poor Outcome After Cardiac Arrest and Targeted Temperature Management: A Multicenter Study on 1,053 Patients. Crit Care Med. 2017. PMID: 28426467. doi:10.1097/CCM.0000000000002335

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。